NY-SERMO
A new survey from Sermo , a physician-first online community and leader in global HCP insights, found that physicians are facing a challenging onslaught of COVID-19 vaccine and treatment misinformation as reported by 3,600+ doctors around the world.
81% of physicians reported feeling that social media misinformation has caused an existential crisis in their profession. More than half (54%) of physicians surveyed reported that a patient has asked them for an unapproved COVID-19 treatment such as Ivermectin and Hydroxychloroquine. Also, more than half (55%) of physicians reported that COVID-19 vaccine misinformation is increasingly becoming an issue when meeting with patients.
Physicians are being bombarded with a variety of COVID-19 vaccine misinformation. The most common misinformation they are hearing from patients is that vaccine safety and effectiveness cannot be trusted because researchers rushed the development of the vaccine, reported by 60% of physicians.
Other types of misinformation heard by physicians from patients include:
- More than half (51%) of physicians reported hearing from patients that they don’t need a COVID-19 vaccine if they’ve already had Covid.
- Misinformation about vaccines modifying your DNA continues to prevail. 45% of physicians reported hearing this from patients.
- Conspiracy theories about microchips in vaccines have made their way to the doctor’s office as 29% of physicians reported hearing this from patients.
- 1 in 5 (20%) physicians reported hearing from patients that the COVID-19 vaccine gives you COVID-19.
- One-third of physicians (34%) reported hearing from patients that vaccines cause infertility. Physicians feel that vaccine hesitancy among pregnant women persists. 61% of physicians reported that pregnant patients are reluctant to get the vaccine.
- COVID-19 vaccine hesitancy is spilling over to other vaccines. 52% of surveyed physicians feel patients who have been hesitant to get COVID-19 vaccines will stop getting other vaccines.
“It’s clear from when we first launched the COVID-19 barometer at the start of the pandemic that misinformation is increasingly posing huge challenges to physicians when treating patients. Physicians feel like they are battling an infodemic that is threatening public health,” says Peter Kirk, Sermo CEO. “The barometer results clearly paint a picture that misinformation is showing up at appointments across the U.S. and the globe at a very local level.”
In addition to battling COVID-19 misinformation, surveyed physicians continue to report they are seeing a significant amount of reluctance among parents to get their kids vaccinated. 61% of physicians reported seeing patients more reluctant to vaccinate their children than themselves. Lack of long-term vaccine safety data in children (45%) was the leading reason physicians believed parents were reluctant to vaccinate their children. This is an increase from a previous Barometer survey fielded in November 2021 when 38% of physicians believed that lack of long-term vaccine safety data was keeping parents from vaccinating their children. 1 in 4 (23%) physicians believed that adverse effects and allergic reactions were a reason that parents weren’t vaccinating their children.
This survey was fielded as part 22 of Sermo’s COVID-19 Barometer and included more than 3,600 physician respondents between March 2 - March 3, 2022. To find out more about the findings of Sermo’s latest COVID-19 Real Time Barometer, visit app.sermo.com/covid19-barometer .
About Sermo:
Sermo turns physician experience, expertise, and observations into actionable insights for the global healthcare community. Engaging with more than 1.3 million HCPs across 150 countries, the company provides physicians with a social platform and unique community that fosters impactful peer-to-peer collaboration & discussions about issues that are important to them and their patients. Sermo offers on-demand access to physicians via a suite of proprietary technology to provide business intelligence that benefits pharmaceutical, healthcare partners, and the medical community at large. To learn more, visit www.sermo.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005281/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AB InBev Reports First Quarter 2025 Results8.5.2025 07:03:00 CEST | Press release
Solid start to the year with EBITDA growth at the top-end of our outlook, continued margin expansion and high-single digit Underlying EPS growth Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507671244/en/ AB InBev Strategic Priorities Regulated information1 “Beer is a passion point for consumers. The strength of the beer category and the continued momentum of our megabrands delivered another quarter of profitable growth. EBITDA increased at the top-end of our outlook and the ongoing optimization of our business drove Underlying EPS growth of 7.1%. The consistent execution of our strategy by our teams and partners drove a solid start to the year and reinforces our confidence in delivering on our outlook for 2025.” – Michel Doukeris, CEO, AB InBev Revenue +1.5% Revenue increased by 1.5% with revenue per hl growth of 3.7%. Reported revenue decreased by 6.3%
Rimini Street and ServiceNow Partner with Apsen Farmacêutica to Deliver a Next-Generation Vision of Enterprise-Wide Workflow Automation7.5.2025 18:55:00 CEST | Press release
Pharmaceutical manufacturer layers ServiceNow over its existing SAP ECC 6 ERP platform, enables intelligent workflow and automation for immediate business impact and avoids low ROI spend on expensive, risky vendor-mandated migration to SAP S/4HANA Knowledge 2025 —Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today at ServiceNow’s annual customer and partner event, Knowledge 2025, announced that Apsen Farmacêutica, a Brazilian pharmaceutical manufacturer, has partnered with Rimini Street and ServiceNow to implement a next-generation vision of enterprise-wide workflow automation. This new vision will enable autonomy across the company to help respond faster to market changes, reduce information silos and improve operational efficiency. This press release features multimedia. View the full release here: https://www.busine
Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials7.5.2025 18:07:00 CEST | Press release
Study conducted by VirTus Respiratory Research demonstrated that vapendavir has potent antiviral activity and improves symptoms in participants with COPD infected with rhinovirus VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa BioSciences with compelling evidence to advance their lead drug candidate, vapendavir, into large scale, late-stage clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507489716/en/ Professor Sebastian Johnston https://www.prnewswire.com/news-releases/altesa-biosciences-details-positive-topline-vapendavir-results-from-phase-2-placebo-controlled-rhinovirus-challenge-study-in-copd-patients-302448650.html Rhinovirus infection is the cause of at least half of the acute respiratory deteriorat
FlightSafety International Announces Major Expansion at Farnborough Airport7.5.2025 17:56:00 CEST | Press release
FlightSafety International (FSI), a global leader in aviation training, is pleased to announce the expansion of its facilities at Farnborough Airport, the home of British aviation and Europe’s leading airport for premium air travel connectivity, highlighting its commitment to enhancing aviation safety and training excellence in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506583636/en/ Rendering: arriving at FlightSafety International The new FSI centre is expected to open in the second quarter of 2027. Lease terms have been finalised and the planning application was submitted in January. Construction is scheduled to start in late 2025 and finish by early 2027. FSI has operated a training centre at Farnborough Airport since 2004. The new facilities will boost training capacity by 40-50%, enabling more aviation professionals access to FSI's world-class training programmes. The current facility is 4,680 square met
Verimatrix Positioned as a Leader and Ace Performer in the 2025 SPARK MatrixTM for In-App Protection by QKS Group7.5.2025 17:45:00 CEST | Press release
The QKS Group SPARK Matrix™ provides competitive analysis and ranking of the leading In-App Protection vendors.Verimatrix is recognized for its comprehensive in-app protection capabilities, earning strong ratings across both Technology Excellence and Customer Impact in the latest SPARK Matrix™.Verimatrix has also been named an Ace Performer – a recognition given to vendors that demonstrate revenue growth potential, partnership strategy, and customer acquisition – all evaluated over the last one-year period or since the previous SPARK Matrix™ assessment. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507970501/en/ Verimatrix positioned as a Leader in the 2025 SPARK Matrix™ for In-App Protection by QKS Group. Verimatrix has been recognized for its comprehensive in-app protection capabilities, earning strong ratings across both Technology Excellence and Customer Impact in the latest SPARK Matrix™. The compan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom